Abstract
Approximately 1 in every 1,000 bp in the human genome differs between individuals. However, only a fraction of these variations are expected to cause disease phenotypes. Such sequence variations are currently utilized for identification of mutated loci in human populations. Furthermore, genotype–phenotype association studies hold promise as prediction models for drug efficacy and may lead to customized patient care. Collectively, these activities encompass the new field of pharmacogenomics. With the potential to increase commercial value of drugs and reduce R&D costs, pharmacogenomics has taken center stage and is now awaiting approval from its audiences. The next frontier of genomics may very well be the integration of the genome map with the phenotypical characteristics of human populations. Drug Dev. Res. 49:46–53, 2000. © 2000 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
